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Abstract
Background—Beneficial HIV treatment outcomes require success at multiple steps along the 
HIV Continuum of Care. Youth living with HIV are a key population, and sites in the Adolescent 
Medicine Trials Network for HIV/AIDS Interventions (ATN) are known for modeling optimum 
HIV adolescent care.
Methods—A longitudinal cohort study conducted at 14 network sites across the United States 
assessed how the later steps of the Continuum of Care were achieved among youth: engagement, 
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treatment and viral load suppression. Youth aged 13–24 who were behaviorally-infected with HIV 
and linked to care at an ATN-affiliated site were eligible to participate.
Results—A total of 467 youth were enrolled and had one year of available data. Most were ages 
22–24 (57%), male (79%), and black/non-Hispanic (71%). Most used alcohol (81%) and 
marijuana (61%) in the three months prior to enrollment, and 40% had a history of incarceration. 
Among this cohort of youth, 86% met criteria for care engagement; among these, 98% were 
prescribed antiretroviral therapy and 89% achieved viral load suppression. Sustained viral load 
suppression at all measured time points was found among 59% with initial suppression. Site 
characteristics were notable for prevalence of adherence counseling (100%), case management 
(100%), clinic-based mental health (93%) and substance use (64%) treatment.
Conclusions—Youth living with HIV in the United States can be successfully treated at health 
care sites with experience, excellence, and important resources and services. Sustained viral load 
suppression may be an important step to add to the Continuum of Care for youth.
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Introduction
Although the HIV pandemic continues, remarkable success has been achieved in areas of 
testing, treatment, and prevention over the past decade. When HIV is treated effectively, 
sustained viral load (VL) suppression minimizes the risk for HIV-associated illness as well 
as disease transmission. With increasing recognition on the importance of treatment as 
prevention1, and because of demonstrated success in HIV treatment in many countries 
throughout the world, the Joint United Nations Programme on HIV/AIDS (UNAIDS) has 
boldly called for an end of the HIV pandemic by 2030.2 Ambitious targets of “90/90/90” 
will need to be achieved by 2020 in order to reach this goal. That is, 90% of persons with 
HIV are diagnosed, 90% of those diagnosed are on treatment, and 90% of those on treatment 
have achieved VL suppression.2
In the United States (US), the HIV/AIDS bureau (HAB) of the Health Resources and 
Services Administration (HRSA) is charged with the administration of the Ryan White 
Federal Program to support those with HIV who do not have the medical insurance and 
other financial resources to manage their disease.3 HAB embraces the HIV Continuum of 
Care (CoC)4 as a model outlining sequential steps that must be achieved in order for 
someone with HIV to move from diagnosis to VL suppression. Along the CoC, once youth 
have been diagnosed and linked to care, specific milestones include engagement in care, 
prescription of antiretroviral therapy (ART), and VL suppression.5
Mugavero and colleagues identify some of the systemic factors in health care delivery that 
can lead to fragmentation of HIV care.6 These authors point out that care engagement itself 
is a dynamic process that includes three components: 1) linkage, 2) retention, and 3) re-
engagement. Initial linkage to care upon a positive HIV test result is a critical component of 
care engagement. Linkage can be followed by ongoing care, and care retention, but someone 
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can also fall out of care at any point. Best practices and systems that support care retention 
and re-engagement are necessary in order to achieve the medical care goal of viral 
suppression6, and this is particularly germane to HIV-infected adolescents and young adults.
Adolescents are a key population globally recognized as being especially vulnerable to HIV 
disease.7 Initial diagnosis and linkage to care is a challenge, and for HIV-infected youth 
aged 15–24 in the US, estimates are that only 51% are aware of their diagnosis and 68% are 
then linked to care.8 Once linked to care and then sufficiently engaged in care, reported rates 
of VL suppression among youth living with HIV (YLWH) in the US have varied widely 
(30.51% to 50.5%) and have raised two major concerns.9, 10 First is the need to understand 
the prevalence and HIV-care impact of other challenges faced by YLWH, including 
substance use, mental illness, lack of social support, and socioeconomic constraints. Second 
is the recognition that critical metrics, such as VL suppression, can only be meaningfully 
interpreted within the context of how well youth progress and achieve successive milestones 
across the CoC.
Healthcare providers who embrace the “90/90/90” targets set by UNAIDS are called upon to 
measure successes, identify and overcome barriers, and share best practices, especially as 
they may apply to HIV among marginalized and underserved populations. In the US, the 
Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) conducted a study 
focused on the latter steps of the CoC in order to evaluate the success of HIV treatment for 
youth at its ATN youth-focused medical centers and clinics as well as to assess factors 
impacting CoC outcomes. Generally located in urban areas with high HIV disease burden, 
many of these sites are known for modeling optimum HIV adolescent care in the US. 
Effective treatment among HIV youth in the US, even at specialized centers, is difficult to 
achieve but critical in order to reach the UNAIDS targets of 90/90/90. This study, ATN 125, 
was conducted to measure and evaluate the effectiveness of initial and ongoing treatment for 
HIV-infected youth at academic medical centers across the US.
Methods
Participants and Recruitment
From February 2015 through February 2016, participants were recruited from 14 adolescent 
medicine clinics located throughout the US in areas with established HIV epidemics. 
Adolescents were approached at clinic visits by research staff and had to be: a) 13 through 
24 years of age; b) behaviorally-infected with HIV; c) currently receiving or planning to 
receive medical care at one of the participating sites; d) ability to understand written and/or 
spoken English, and f) give permission for research staff to access their medical records in 
order to be included. The study was approved by the Institutional Review Boards (IRBs) at 
each of the participating clinics.
Study Procedures
After the initial screening process, all eligible youth were invited to participate, and consent 
was obtained. Participants then completed an audio-computer assisted self-interview 
(ACASI) to assess multiple measures described below. Participants were given a small 
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incentive, determined by each site and approved by their IRB, for their time and effort 
completing the assessment.
Research staff abstracted biomedical and visit appointment information from the 
participants’ medical record, including: date of initial HIV diagnosis; date of first HIV-
related medical care visit; initial VL, initial CD4 count (percentage and absolute count, if 
available). For participants already in care, additional data was collected retrospectively up 
to 26 weeks prior to enrollment that included: all VL results, CD4 counts, any diagnosis of a 
sexually transmitted infection (STI), treatment assessment (clinician prescribed and subject 
acceptance of/adherence to ART), and subject healthcare utilization.
Measures
Demographic characteristics—Participants’ demographic characteristics were 
ascertained including age, gender, ethnicity, race, education, employment status, annual 
income, and living situation. Additional questions were asked about age at time of HIV 
diagnosis, HIV disclosure, and any history of incarceration.
Substance Use, Mental Health, and Adherence—The Brief Symptoms Inventory 
(BSI)11 was included as an assessment of mental health; the Alcohol, Smoking, and 
Substance Involvement Screening Test (ASSIST)12 measured substance use; and questions 
were included to assess readiness and self-efficacy/ability for health care.
Statistical Analysis
For each patient, a one-year study period was defined. The start of the study period was the 
date of the patient’s first HIV-related visit if they were new to care or were reengaging in 
care. For participants already engaged in care at enrollment, up to 6 months (180 days) of 
data was collected retrospectively and the first date for which data were collected was 
considered the subject’s start date for the study. Patients were required to have at least one 
year of possible follow-up on study to be included in this analysis. Originally the study was 
designed to collect data for two years on all subjects, however, the study was ended 
prematurely due to funding constraints, and so full-year follow-up data was not available for 
all who enrolled.
Steps in the CoC were defined as follows. Engagement in care was defined using the HRSA 
HAB measure13 that requires at least two HIV primary care visits, separated by at least 90 
days in a one-year measurement period. Patients were considered to have been prescribed 
ART if they reported a health care provider prescribed ART at any time since the last 
medical record abstraction, including continuing previously prescribed ART. Three different 
viral suppression outcomes were used among participants who either were on ART at 
enrollment or initiated ART during the study period: (1) attained suppression during the 
study period (at least one plasma HIV-1 RNA VL <200 copies/ml); (2) at least 50% of VLs 
during the study period at <200 copies/ml; and (3) 100% of VLs during the study period at 
<200 copies/ml. Steps in the CoC were treated as conditional; that is, only patients who 
completed the previous step(s) were considered at each subsequent step.
Lally et al. Page 4
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2019 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Variables were summarized using frequency counts and percentages. Completion of each 
step of the CoC (yes vs. no) was modeled separately using logistic regression models. 
Successful completion of the step was modeled as the event. Independent variables 
considered included demographic measures such as age, gender, race, ethnicity, living 
arrangement, income, and education as well as behavioral measures including disclosure, 
alcohol and substance use, mental health, and ability to keep healthcare appointments. 
Because this was a multi-site study with patients clustered within sites, stratification by site 
was included in all models. Univariate results were used to construct separate multi-variable 
(MV) logistic models for each step in the CoC. Data on all variables included in the MV 
models are shown in the tables. Odds ratios and associated 95% confidence intervals are 
reported. All analyses were performed using SAS®, version 9.4 (SAS Institute, Cary, NC).
Results
The study enrolled 924 youth. With early termination of the study, a full year of data was 
available for 467 youth. Demographic characteristics and other self-reported experiences 
determined by the baseline ACASI are presented in Table 1. Most participants (57%) were 
between the ages of 22 and 24, while 16% were teenagers. The majority were male (79%) 
and Black/Non-Hispanic (71%), with a high school education or less (63%). While 58% 
were employed, half reported earning less than $6000 per year. A spectrum of living 
situations were endorsed, with 43% living in their parents’ home and 29% living in their 
own house/ apartment. Many reported a history of incarceration (40%).
Half of the youth (51%) have been diagnosed with HIV for less than three years as 
determined by record abstraction of the date of initial diagnosis as compared to the date of 
enrollment. ACASI results indicate that most (85%) had disclosed their status to someone, 
and most felt ready to attend medical appointments (80%). Prevalent in this cohort are 
depressive symptoms (43%), alcohol use (81%), marijuana use (61%), and use of other 
drugs (22%).
Figure 1 depicts CoC assessments beginning with the step of retention in care. Among this 
cohort, 86% (n=403) met the HAB definition for care engagement, having at least two care 
visits 90 days apart within a one-year period. Of these youth meeting the HAB definition of 
engagement, 98% were prescribed ART (394/403), and 89% achieved VL suppression 
(360/403). Further evaluation demonstrated that 81% of youth meeting the HAB definition 
of engagement achieved VL suppression for at least half of the VL measurements taken 
during the study period, and 59% meeting the HAB definition of engagement achieved VL 
suppression for all VL measurements.
Table 2 describes the factors found to be significantly associated with each step along the 
CoC from the MV logistic models. Being completely ready to go to medical appointments 
(AOR 2.17, 1.13–4.17) was associated with meeting the HAB criteria for engagement in 
care. Among those engaged in care, being male (AOR 5.85, 1.04–33.33), using alcohol less 
than 1–2 times per month vs. daily or almost daily (AOR 21.65, 1.55–302.51), and using 
alcohol weekly vs. daily or almost daily (AOR 26.63, 1.18–600.18) were each associated 
with being started on ART. Factors associated with achieving VL suppression on at least half 
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of the measures included having no income vs. an income of more than $12,000 per year 
(AOR 4.18, 1.55–11.24), being very confident about ability to keep a medical appointment 
vs. being “pretty sure” (OR 2.82, 1.44–5.56), and having never been incarcerated (AOR 
1.99, 1.09–3.62). Factors associated with achieving VL suppression at all measurements 
were living in one’s own house/apartment vs. other (other includes foster home/ group 
home, halfway house, shelter, on the street) (AOR 3.42, 1.27–9.26) and never having been 
incarcerated (AOR 2.08, 1.32–3.28).
Further evaluation of incarceration history associated with achieving 50% VL suppression 
showed that having a history or being in jail 2–5 times (AOR 0.41, 0.18–1.95) ater than 5 
times (AOR 0.17, 0.04–0.70) compared to never being incarcerated was associated with 
decreased success. Being incarcerated once compared to never being incarcerated had no 
significant association. When looking at 100% VL suppression, having a history of being in 
jail one time (AOR 0.52, 0.30–0.91) or 2–5 times (AOR 0.46, 0.24–0.88) compared to never 
being incarcerated was associated with decreased success, while being incarcerated more 
than five times did not reach statistical significance. There were no associations found with a 
recent history of incarceration (in last 90 days) and any of the VL suppression outcome 
measures.
Engagement in care was associated with VL suppression (p < 0.001). Among the 64 youth 
who did not meet the HAB criteria for care engagement, 91% (n=58) were prescribed ART, 
58% (n=37) achieved VL suppression, 55% (n=35) achieved VL suppression for at least half 
of the VL measurements taken during the study period, and 42% (n=27) achieved VL 
suppression for all VL measurements.
There were some differences between sites in CoC outcomes when they were looked at in 
univariate logistic modeling but they were not consistent for all CoC outcomes and thus 
were accommodated for by stratifying by site for all further univariate and multivariable 
logistic modeling. Characteristics of the sites include the fact that all were affiliated with an 
academic medical center, and all were supported with Ryan White funding. Figure 2 
highlights some additional site characteristics. All had clinic-based case management, and 
patient navigators, and all offered specific counseling for medication adherence. Most also 
offered clinic-based mental health (93%) and substance use treatment (64%), and also 
utilized peer support groups (86%).
Discussion
This study has three key findings. First, once youth are successfully tested for HIV and 
linked to care, many engage in care and remain in care. However, even at optimal sites, the 
rate of engagement is less than 90%. Second, most youth who engage in care will achieve 
viral suppression. Notably, this rate is also less than 90%, and initial suppression is not a 
surrogate for sustained suppression. Third, a remote history of incarceration is an important 
risk for HIV treatment failure among youth.
Youth face multiple challenges that trained and experienced care providers can help them 
overcome in order to achieve the medical goal of viral suppression. One can compare the 
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ambitious UNAIDS targets of “90/90/90” to the success achieved by previously supported 
ATN sites across the US in terms of HIV treatment and suppression. First, any success in 
care must be contextualized in terms of the large proportion of HIV-infected youth who are 
not diagnosed or ever linked to care. UNAIDS call for 90% of those living with HIV to 
know their status by 2020, while epidemiologic data estimates that only 51% of HIV-
infected youth in the U.S. are aware of their status.8 Next, UNAIDS calls for 90% of all 
persons diagnosed with HIV to receive sustained antiretroviral therapy. Therapy requires 
linkage to care, and while not part of this study, it is notable that the ATN has done separate 
work in this area. Innovative implementation programs such as the Strategic Multisite 
Initiative for Identification, Linkage and Engagement or SMILE have been described 
elsewhere14 and will be detailed further in forthcoming publications. Still, once linked to 
care at ATN sites and engaged in care, youth in our study were able to achieve a noteworthy 
treatment milestone of 97% treated. Notably, youth who do not meet HAB criteria 
engagement have lower rates of treatment and suppression, and they are a potential group 
that may benefit from targeted interventions. Finally, UNAIDS calls for achievement of viral 
suppression among 90% of those receiving treatment by 2020. Again, the cohort we studied 
was just shy of meeting this goal in 2015, with 89% achieving suppression.
Earlier studies done by the ATN suggested that challenges faced by YLWH were actually 
preventing successful HIV treatment. Kahana and colleagues (2015) described data from a 
cross-sectional cohort study of 2,196 perinatally- and behaviorally-infected YLWH from 20 
ATN-affiliated adolescent medicine clinics which showed that while 82.4% of perinatally- 
and 49.1% of behaviorally-infected youth reported current ART use, only 37.0% of 
perinatally- and 27.1% of behaviorally-infected youth were virologically suppressed.15 In an 
earlier study, it was reported that between 2002 and 2008, only 69% of behaviorally-infected 
youth who met clinical criteria (having at least 2 CD4 measurements, 350 cells/mm3) had 
initiated ART (compared with 79% of adults).16 Saberi et al. examined data from 1,317 
HIV-infected individuals who were 12–24 years old (mean age = 20.0 years), were on ART, 
and were behaviorally-(52.7%) and perinatally-(39.1%) infected with HIV. Mean self-
reported ART adherence over the prior seven days was 86.1% (median = 100%); 50.5% of 
the sample had an undetectable plasma HIV RNA.10 In this study, a cohort of youth was 
followed for a full year to determine how well they achieved treatment milestones along the 
CoC.
The current study was conducted from 2015–2016, and HIV treatment guidelines had 
evolved by then to essentially support universal treatment.17 This may be a critical factor, 
especially to clarify the almost complete prescribing of ART to this cohort. The availability 
of newer medications that were better tolerated supported the implementation of these newer 
guidelines. Temporal bias is therefore likely to account in part for the higher rates of 
suppression found among our cohort as compared to ones described even just a few years 
ago. The finding that young men were more likely to be prescribed therapy than young 
women is interesting to consider, although prescribing rates were above 95% for both 
groups. Other reasons that the VL suppression rates found in this study are higher than many 
others reported in the literature may include the intensive support services available. Sites 
universally reported the availability of adherence counseling, clinic-based case management 
services and clinic-based patient navigators, and most also offered clinic-based mental 
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health services and clinic-based substance use treatment. These support services, offered at 
highly experienced sites and often integrated into best practices, may also explain the 
relatively high rates of VL suppression that we observed.
Achieving initial VL suppression is an important first step to sustained suppression. Almost 
90% (89%) of this cohort did achieve VL suppression, but this dropped to 81% when 
measured at least half of the time, and further to 59% when measured all of the time. The 
UNAIDS target of 90% VL suppression is clearly important, but at least for youth it must be 
recognized that this is not a surrogate for durable VL control. Single point in time 
suppression is not sufficient. Adding the step of Sustained Suppression to the CoC for 
YLWH will not only allow for more meaningful measurements, but also support further 
research to assess how this higher goal might be achieved. It may be that select support 
services are necessary.
In addition to studies done by the ATN, work by the Centers for Disease Control and 
Prevention and others have demonstrated challenges to successful HIV treatment based upon 
age, race, substance use, and mental health.18–23 Analysis of our large cohort notably lacks 
associations with successful treatment based on age (although the range was quite narrow), 
race/ethnicity, education, mental health indicators, and substance use other than alcohol. 
There were also no significant differences by site. Sites were all affiliated with academic 
medical centers and were well-resourced with clinic-based support services for youth facing 
challenges with mental health, substance use, adherence, and other medical and/or 
socioeconomic needs that could be addressed by case management. Results of this study 
arguably support the need to provide clinic-based supportive services to YLWH in order to 
achieve treatment success.
Factors that did remain significantly associated with treatment success included living 
situation, heavy alcohol use, and incarceration history. Living situations that include 
supportive families are likely to be helpful. Stronger case management and enhanced 
substance use treatment might also support the first two factors. Incarceration, though, needs 
substantial work. In a comprehensive review article, Wakerman and Rich consider the 
epidemiology of HIV in US correctional facilities.24 These authors describe wide state-by-
state variations in how HIV is handled in jails and prisons across the US and note that 
“tremendous variability results in dramatic differences in the provision of care and health 
outcomes.” YLWH who are incarcerated not as juveniles, but as adults, may be especially 
vulnerable to the stigma and violence the authors describe when confidentiality is not 
maintained. Further research among YLWH in jails and prisons is needed in order to 
optimize care.
The current study’s findings must be interpreted in light of some limitations. First, our 
findings may not be generalizable beyond the adolescents and young adults who participated 
in this study and are receiving care at one of the participating ATN sites. Future work needs 
to be expanded to include YLWH who are not currently in care, who are in care at a non-
academic/non-adolescent focused clinic in the US, and YLWH who live outside of the US. 
Second, some of our data are based upon self-report measures, which may be subject to bias 
or errors. We used ACASI to minimize this possibility and encouraged participants to 
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answer questions honestly and carefully. Third, the study was stopped prematurely due to 
budgetary restrictions so we did not have longer-term longitudinal data as originally planned 
for a substantial number of participants and this also limited further subgroup analyses such 
as among those who only initiated ART during the study period. Still, our cohort with a full 
12 months of follow-up is large and geographically representative of urban areas across the 
US. Finally, participant enrollment could have been subject to bias as sites were aware that 
CoC outcomes would be evaluated and compared across sites. Still, all sites were strongly 
encouraged to enroll participants regardless of their medication adherence or viral load 
suppression.
YLWH are a priority population for us to treat, particularly young racial and ethnic minority 
men who have sex with men in the US. Testing and linkage to care is difficult, and if we 
only achieve treatment success in a minority of HIV–infected youth then true success cannot 
be claimed. However, ATN sites have achieved remarkable results while caring for our 
YLWH. They are to be commended, and also asked to share further insights and best 
practices that may not have been captured in the assessment of site characteristics done as 
part of this study. Further studies with this dataset are being done in an attempt to identify 
key elements of the care and services being provided at these sites. The CoC has been a 
transformative framework for HIV care. Although we found that youth can achieve VL 
suppression without meeting the criteria for engagement, engagement was predictive of VL 
suppression. Ultimately, sustained suppression is more meaningful to achieve long-term 
health benefit. Our findings suggest that sustained suppression should be added as the final 
step to the CoC, at least for youth.
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Figure 1. 
Continuum of Care for HIV-infected Youth at ATN clinic sites
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Figure 2. 
Selected Clinic Characteristics of 14 ATN Sites in the US
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Table 1
Demographic characteristics (N=467)
Cohort Characteristics n (%)
Age
  16–17 14 (3.0%)
  18–19 59 (12.6%)
  20–21 125 (26.8%)
  22–24 268 (57.4%)
Gender (at birth)
    Male 371 (79.4%)
    Female 96 (20.6%)
Gender Identity
    Male 344 (73.7%)
    Female 100 (21.4%)
    Trans female 16 (3.4%)
    Gender non-conforming 3 (0.6%)
    Other 4 (0.9%)
Race/Ethnicity
    Black/non-Hispanic 330 (70.7%)
    Hispanic 81 (17.3%)
    White/non-Hispanic 16 (3.4%)
    Other/non-Hispanic 34 (7.3%)
    Did not identify 6 (1.3%)
Education
    Less than high school 85 (18.2%)
    High school or GED 208 (44.5%)
    More than high school 170 (36.4%)
    None, no formal schooling 3 (0.6%)
    Don’t know/refuse to answer 1 (0.2%)
Employment Status
    Employed 271 (58%)
Income (annual)
    0 < $600 90 (19.3%)
    $600–$5,999 145 (31.0%)
    $6,000–$35,999 156 (33.4%)
    >$36,000 8 (1.7%)
    Refuse to answer/don’t know 68 (14.6%)
Living situation (current)
    Own house/apartment 137 (29.3%)
    Parents’ house/apartment 199 (42.6%)
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Cohort Characteristics n (%)
    Other family member(s) house/apartment 50 (10.7%)
    Non-family member’s house/apartment 43 (9.2%)
    Other 37 (7.9%)
    Refuse to answer 1 (0.2%)
Incarceration History
  Ever been in jail/prison?
      Yes 184 (40.0%)
        HIV Treatment Factors
Number of Years Infected with HIV
  ≤ 1 year 134 (28.7%)
  1–2 years 103 (22.1%)
  2–4 years 122 (26.2%)
  5 or more 107 (23.0%)
Have you disclosed your HIV status to anyone?
  yes 396 (85.0%)
  no 70 (15.0%)
Health Care Appointment Readiness and Ability
Readiness: I am ready to go to medical appointments 369 (80.0%)
Self-Efficacy: I am very sure that I can keep doctor appointments 335 (72.0%)
  Select Items from Brief Symptom Inventory
BSI_Somatization 158 (34.5%)
BSI_Depression 199 (43.1%)
BSI_Anxiety 143 (31.0%)
        Select Items from the ASSIST
How often have you used alcohol in past 3 months
    Never 89 (19.2%)
    Once or twice per month 269 (58.0%)
    Weekly 91 (19.6%)
    Almost Daily or Daily 15 (3.2%)
How often have you used marijuana past 3 months
  Never 180 (39.1%)
  Once or twice per month 101 (21.9%)
  Weekly 38 (8.2%)
  Almost Daily or Daily 142 (30.8%)
How often used Cocaine, Amphetamines, Inhalants, Sedatives, Hallucinogens, Opiates in past 3 month
  Never 361 (78.0%)
  Once or twice per month 87 (18.8%)
  Weekly 10 (2.2%)
  Almost Daily or Daily 5 (1.1%)
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Missing values: Age 1, Incarceration 2, Number of years HIV+ 1, Disclosed 1, Ready to go to appointments 5, self-efficacy 2, BSI Somatization 9, 
BSI Depression 5, BSI Anxiety 5, ASSIST alcohol 3, ASSIST marijuana 6, ASSIST other drugs 4.
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Table 2
Factors significantly associated with each step of the CoC for youth*
Stage of the
COC
Significant Factor(s) AOR 95% CI P Value
HAB met Completely Ready to go to Med Appt vs Other 2.17 1.13–4.17 0.02
Prescribed Therapy
Gender Male vs Female 5.85 1.04–33.33 0.05
Alcohol 1–2 times per month vs. daily or almost daily 21.65 1.55–302.51 0.02
Alcohol weekly vs. daily or almost daily 26.63 1.18–600.18 0.04
Achieving VL suppression 50% of the time
No or little Income vs. Income of at least $1000/ month or 
more
4.18 1.55–11.24 <0.01
Very sure can keep medical appointments vs. pretty sure 2.82 1.43–5.56 <0.01
Jail ever No vs. Yes 1.99 1.09–3.62 0.02
Achieving VL Suppression 100% of the 
time
Live in own house or apartment vs other 3.42 1.27–9.26 0.02
Jail ever No vs. Yes 2.08 1.32–3.28 < 0.01
OR: odds ratio; CI: confidence interval; VL: viral load; HAB: HIV/AIDS Bureau measure
*Separate multivariate logistic regression models were fit for each step of the CoC. Successfully completing the step was the event. Each model 
included site as a stratification factor. In addition to the variables shown: the “HAB met” model also included confidence about ability to keep a 
medical appointment; the “Prescribed Therapy” model also included BSI Somatization, BSI Depression, BSI Anxiety, and the BSI general 
symptoms index; the “Achieving VL suppression 50% of the time” model also included living arrangement, years HIV+, and alcohol use.
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